References
- Tammenmaa‐Aho, I., Asher, R., Soares‐Weiser, K., & Bergman, H. (2018). Cholinergic medication for antipsychotic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews, (3), CD000207. doi:10.1002/14651858.CD000207.pub2
- Carbon, M., Hsieh, C. H., Kane, J. M., & Correll, C. U. (2017). Tardive Dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis. The Journal of Clinical Psychiatry, 78(3), e264–e278. doi:10.4088/JCP.16r10832
- Citrome, L. (2017). Clinical management of tardive dyskinesia: Five steps to success. Journal of the Neurological Sciences, 383, 199–204. doi:10.1016/j.jns.2017.11.019
- Jankelowitz, S. K. (2013). Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatric Disease and Treatment, 9, 1371–1380. doi:10.2147/NDT.S30767
- Lally, J., & MacCabe, J. H. (2015). Antipsychotic medication in schizophrenia: A review. British Medical Bulletin, 14 (1), 169–179. doi:10.1093/bmb/ldv017
- Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet, 379(9831), 2063–2071. doi:10.1016/S0140-6736(12)60239-6
- Macaluso, M., Flynn, A., & Preskorn, S. H. (2017). Tardive dyskinesia a historical perspective. Journal of Psychiatric Practice, 23 (2), 119–121. doi:10.1097/PRA.0000000000000224
- NICE. (2014). Psychosis and schizophrenia in adults: Prevention and management, clinical guideline CG178. Accessed April 14, 2019, from https://www.nice.org.uk/guidance/cg178/chapter/1-Recommendations#promoting-recovery-and-possible-future-care-2.